417 related articles for article (PubMed ID: 28126818)
1. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.
Wang TT; Sewatanon J; Memoli MJ; Wrammert J; Bournazos S; Bhaumik SK; Pinsky BA; Chokephaibulkit K; Onlamoon N; Pattanapanyasat K; Taubenberger JK; Ahmed R; Ravetch JV
Science; 2017 Jan; 355(6323):395-398. PubMed ID: 28126818
[TBL] [Abstract][Full Text] [Related]
2. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
3. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
[TBL] [Abstract][Full Text] [Related]
4. Antibody fucosylation predicts disease severity in secondary dengue infection.
Bournazos S; Vo HTM; Duong V; Auerswald H; Ly S; Sakuntabhai A; Dussart P; Cantaert T; Ravetch JV
Science; 2021 Jun; 372(6546):1102-1105. PubMed ID: 34083490
[TBL] [Abstract][Full Text] [Related]
5. Determination of antibody concentration as the main parameter in a dengue virus antibody-dependent enhancement assay using FcγR-expressing BHK cells.
Moi ML; Takasaki T; Saijo M; Kurane I
Arch Virol; 2014 Jan; 159(1):103-16. PubMed ID: 23900750
[TBL] [Abstract][Full Text] [Related]
6. Indices of anti-dengue immunoglobulin G subclasses in adult Mexican patients with febrile and hemorrhagic dengue in the acute phase.
Posadas-Mondragón A; Aguilar-Faisal JL; Chávez-Negrete A; Guillén-Salomón E; Alcántara-Farfán V; Luna-Rojas L; Ávila-Trejo AM; Del Carmen Pacheco-Yépez J
Microbiol Immunol; 2017 Oct; 61(10):433-441. PubMed ID: 28881485
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
Fink AL; Williams KL; Harris E; Alvine TD; Henderson T; Schiltz J; Nilles ML; Bradley DS
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
[TBL] [Abstract][Full Text] [Related]
8. Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA.
Moi ML; Lim CK; Kotaki A; Takasaki T; Kurane I
J Virol Methods; 2010 Feb; 163(2):205-9. PubMed ID: 19781573
[TBL] [Abstract][Full Text] [Related]
9. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.
Chaichana P; Okabayashi T; Puiprom O; Sasayama M; Sasaki T; Yamashita A; Ramasoota P; Kurosu T; Ikuta K
PLoS One; 2014; 9(3):e92173. PubMed ID: 24642752
[TBL] [Abstract][Full Text] [Related]
10. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.
Lau L; Green AM; Balmaseda A; Harris E
J Clin Virol; 2015 Aug; 69():63-7. PubMed ID: 26209381
[TBL] [Abstract][Full Text] [Related]
11. Antibody-enhanced binding of dengue-2 virus to human platelets.
Wang S; He R; Patarapotikul J; Innis BL; Anderson R
Virology; 1995 Oct; 213(1):254-7. PubMed ID: 7483271
[TBL] [Abstract][Full Text] [Related]
12. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of dengue-virus-specific IgG and IgA during pre-defervescence associated with primary dengue hemorrhagic fever.
Bachal R; Alagarasu K; Singh A; Salunke A; Shah P; Cecilia D
Arch Virol; 2015 Oct; 160(10):2435-43. PubMed ID: 26175069
[TBL] [Abstract][Full Text] [Related]
14. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections.
Saito M; Oishi K; Inoue S; Dimaano EM; Alera MT; Robles AM; Estrella BD; Kumatori A; Moji K; Alonzo MT; Buerano CC; Matias RR; Morita K; Natividad FF; Nagatake T
Clin Exp Immunol; 2004 Nov; 138(2):299-303. PubMed ID: 15498040
[TBL] [Abstract][Full Text] [Related]
15. Serological characterization of dengue virus infections observed among dengue hemorrhagic fever/dengue shock syndrome cases in upper Myanmar.
Ngwe Tun MM; Thant KZ; Inoue S; Kurosawa Y; Lwin YY; Lin S; Aye KT; Thet Khin P; Myint T; Htwe K; Mapua CA; Natividad FF; Hirayama K; Morita K
J Med Virol; 2013 Jul; 85(7):1258-66. PubMed ID: 23595687
[TBL] [Abstract][Full Text] [Related]
16. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.
Zellweger RM; Prestwood TR; Shresta S
Cell Host Microbe; 2010 Feb; 7(2):128-39. PubMed ID: 20153282
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune pathogenesis in dengue virus infection.
Lin CF; Wan SW; Cheng HJ; Lei HY; Lin YS
Viral Immunol; 2006; 19(2):127-32. PubMed ID: 16817755
[TBL] [Abstract][Full Text] [Related]
18. Characterization of dengue virus infections in a sample of patients suggests unique clinical, immunological, and virological profiles that impact on the diagnosis of dengue and dengue hemorrhagic fever.
Senaratne T; Wimalaratne H; Alahakoon DG; Gunawardane N; Carr J; Noordeen F
J Med Virol; 2016 Oct; 88(10):1703-10. PubMed ID: 26990973
[TBL] [Abstract][Full Text] [Related]
19. Dengue hemorrhagic fever: comparison of patients with primary and secondary infections.
Khurram M; Qayyum W; Hassan SJ; Mumtaz S; Bushra HT; Umar M
J Infect Public Health; 2014; 7(6):489-95. PubMed ID: 24999118
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
Goncalvez AP; Engle RE; St Claire M; Purcell RH; Lai CJ
Proc Natl Acad Sci U S A; 2007 May; 104(22):9422-7. PubMed ID: 17517625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
